Literature DB >> 18259974

Pneumocystis: a novel pathogen in chronic obstructive pulmonary disease?

Alison Morris1, Frank C Sciurba, Karen A Norris.   

Abstract

Chronic obstructive pulmonary disease (COPD) results in significant morbidity and mortality. Smoking has long been recognized as the primary risk factor for development of COPD, but factors determining the severity or pattern of disease in smokers are largely unknown. Recent interest has focused on the potential role of infectious agents and the associated host response in accelerating progression of airway obstruction or in perpetuating its progression following discontinuation of tobacco exposure. Pneumocystis jirovecii is a fungal pathogen that causes pneumonia in immunocompromised individuals. Recent evidence has linked this organism with COPD. Using sensitive molecular techniques, low levels of Pneumocystis have been detected in the respiratory tract of certain individuals and termed colonization. Several findings support the theory that colonization with Pneumocystis is involved in the "vicious circle" hypothesis of COPD in which colonization with organisms perpetuates an inflammatory and lung remodeling response. Pneumocystis colonization is more prevalent in smokers and in those with severe COPD. The presence of Pneumocystis in the lungs, even at low levels, produces inflammatory changes similar to those seen in COPD, with increases in numbers of neutrophils and CD8(+) lymphocytes. HIV-infected subjects who have had PCP develop permanent airway obstruction, and HIV-infected patients have a high prevalence of both emphysema and Pneumocystis colonization. In addition, a non-human primate model of colonization shows development of airway obstruction and radiographic emphysema. Additional studies are needed to confirm the role of Pneumocystis in the pathogenesis of COPD, given that this agent might be a treatable co-factor in disease progression.

Entities:  

Mesh:

Year:  2008        PMID: 18259974      PMCID: PMC2602875          DOI: 10.1080/15412550701817656

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  85 in total

1.  Lymphocyte response in subjects with chronic pulmonary disease colonized by Pneumocystis jirovecii.

Authors:  Jose M Varela; Nieves Respaldiza; Berta Sánchez; Carmen de la Horra; Marco Montes-Cano; Manuel Rincón; Javier Dapena; Concepción González-Becerra; Francisco J Medrano; Enrique Calderón
Journal:  J Eukaryot Microbiol       Date:  2003       Impact factor: 3.346

2.  Pneumocystis colonization in HIV-infected patients.

Authors:  Laurence Huang; Kristina Crothers; Alison Morris; Gena Groner; Melissa Fox; Joan R Turner; Cynthia Merrifield; Shary Eiser; Patrizia Zucchi; Charles B Beard
Journal:  J Eukaryot Microbiol       Date:  2003       Impact factor: 3.346

3.  Immune responses to Pneumocystis colonization and infection in a simian model of AIDS.

Authors:  Sangita P Patil; Kathyrn F Board; Irina P Lebedeva; Karen A Norris
Journal:  J Eukaryot Microbiol       Date:  2003       Impact factor: 3.346

4.  Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease.

Authors:  Tom M A Wilkinson; Irem S Patel; Mark Wilks; Gavin C Donaldson; Jadwiga A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  2003-01-24       Impact factor: 21.405

5.  Experimental Pneumocystis carinii pneumonia in simian immunodeficiency virus-infected rhesus macaques.

Authors:  Kathryn F Board; Sangita Patil; Irina Lebedeva; Saverio Capuano; Anita M Trichel; Michael Murphey-Corb; Premeela A Rajakumar; JoAnne L Flynn; Constantine G Haidaris; Karen A Norris
Journal:  J Infect Dis       Date:  2003-02-07       Impact factor: 5.226

6.  Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: a prospective study.

Authors:  N A Maskell; D J Waine; A Lindley; J C T Pepperell; A E Wakefield; R F Miller; R J O Davies
Journal:  Thorax       Date:  2003-07       Impact factor: 9.139

7.  Prevalence and clinical predictors of Pneumocystis colonization among HIV-infected men.

Authors:  Alison Morris; Lawrence A Kingsley; Gena Groner; Irina P Lebedeva; Charles B Beard; Karen A Norris
Journal:  AIDS       Date:  2004-03-26       Impact factor: 4.177

8.  Characterization of transmission of Pneumocystis carinii f. sp. muris through immunocompetent BALB/c mice.

Authors:  F Gigliotti; A G Harmsen; T W Wright
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

Review 9.  Chronic obstructive pulmonary disease: molecular and cellular mechanisms.

Authors:  P J Barnes; S D Shapiro; R A Pauwels
Journal:  Eur Respir J       Date:  2003-10       Impact factor: 16.671

10.  Detection of Pneumocystis DNA in samples from patients suspected of bacterial pneumonia--a case-control study.

Authors:  Jannik Helweg-Larsen; Jørgen Skov Jensen; Birthe Dohn; Thomas L Benfield; Bettina Lundgren
Journal:  BMC Infect Dis       Date:  2002-11-25       Impact factor: 3.090

View more
  34 in total

1.  Persistent pneumocystis colonization leads to the development of chronic obstructive pulmonary disease in a nonhuman primate model of AIDS.

Authors:  Timothy W Shipley; Heather M Kling; Alison Morris; Sangita Patil; Jan Kristoff; Siobhan E Guyach; Jessica E Murphy; Xiuping Shao; Frank C Sciurba; Robert M Rogers; Thomas Richards; Paul Thompson; Ronald C Montelaro; Harvey O Coxson; James C Hogg; Karen A Norris
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

2.  The state of research for AIDS-associated opportunistic infections and the importance of sustaining smaller research communities.

Authors:  Anthony P Sinai; Edna S Kaneshiro; Honorine Ward; Louis M Weiss; Melanie T Cushion
Journal:  Eukaryot Cell       Date:  2011-12-09

3.  Circulating genotypes of Pneumocystis jirovecii and its clinical correlation in patients from a single tertiary center in India.

Authors:  Y Singh; B R Mirdha; R Guleria; S Khalil; A Panda; R Chaudhry; A Mohan; S K Kabra; L Kumar; S K Agarwal
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-04-11       Impact factor: 3.267

4.  Pneumocystis workshop: 10th anniversary summary.

Authors:  James M Beck; Melanie T Cushion
Journal:  Eukaryot Cell       Date:  2009-01-23

5.  Trimethoprim-sulfamethoxazole treatment does not reverse obstructive pulmonary changes in pneumocystis-colonized nonhuman primates with SHIV infection.

Authors:  Heather M Kling; Timothy W Shipley; Siobhan Guyach; Rebecca Tarantelli; Alison Morris; Karen A Norris
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-01       Impact factor: 3.731

6.  B Lymphocytes Are Required during the Early Priming of CD4+ T Cells for Clearance of Pneumocystis Infection in Mice.

Authors:  Michael M Opata; Melissa L Hollifield; Frances E Lund; Troy D Randall; Robert Dunn; Beth A Garvy; David J Feola
Journal:  J Immunol       Date:  2015-06-03       Impact factor: 5.422

Review 7.  Analysis of current antifungal agents and their targets within the Pneumocystis carinii genome.

Authors:  Aleksey Porollo; Jaroslaw Meller; Yogesh Joshi; Vikash Jaiswal; A George Smulian; Melanie T Cushion
Journal:  Curr Drug Targets       Date:  2012-11       Impact factor: 3.465

8.  Type 1 interferons suppress accelerated osteoclastogenesis and prevent loss of bone mass during systemic inflammatory responses to Pneumocystis lung infection.

Authors:  Michelle Wilkison; Katherine Gauss; Yanchao Ran; Steve Searles; David Taylor; Nicole Meissner
Journal:  Am J Pathol       Date:  2012-05-22       Impact factor: 4.307

9.  Echinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection.

Authors:  Melanie T Cushion; Michael J Linke; Alan Ashbaugh; Tom Sesterhenn; Margaret S Collins; Keeley Lynch; Ronald Brubaker; Peter D Walzer
Journal:  PLoS One       Date:  2010-01-29       Impact factor: 3.240

10.  MyD88 signaling regulates both host defense and immunopathogenesis during pneumocystis infection.

Authors:  Sheila N Bello-Irizarry; Jing Wang; Carl J Johnston; Francis Gigliotti; Terry W Wright
Journal:  J Immunol       Date:  2013-11-29       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.